高危与极高危前列腺癌根治术与放疗后的生存比较
基于SEER数据库2010-2016年24,407例NCCN高危前列腺癌患者,比较根治性前列腺切除术(RP)与外照射放疗(EBRT)的癌症特异性死亡率(CSM)。倾向评分匹配后,RP在整体NCCN高危队列和JH极高危亚组中CSM显著优于EBRT,但在JH高危亚组中无显著差异。
要点
- 整体NCCN高危队列中,RP的5年CSM为2.3%,EBRT为4.1%,多变量HR 0.68 favoring RP。
- JH极高危亚组中,RP的5年CSM为3.5%,EBRT为6.0%,多变量HR 0.58 favoring RP。
- JH高危亚组中RP与EBRT的CSM无显著差异(HR 0.7,95%CI 0.39-1.25,p=0.2)。
核心结论
- 在整体NCCN高危队列和JH极高危亚组中,RP较EBRT具有CSM优势。
- 在JH高危亚组中,RP与EBRT的CSM无显著差异。
研究设计与样本
- 基于SEER数据库(2010-2016)的回顾性队列研究,纳入24,407例NCCN高危前列腺癌患者。
- 其中10,300例(42%)为JH高危,14,107例(58%)为JH极高危;9,823例(40%)接受RP,14,584例(60%)接受EBRT。
- 采用1:1倾向评分匹配(年龄、PSA、临床T和N分期、活检Gleason评分)后,用累积发生率图和竞争风险回归分析CSM。
主要发现
- 整体NCCN高危队列:RP的5年CSM为2.3%,EBRT为4.1%,多变量HR 0.68(95%CI 0.54-0.86,p<0.001) favoring RP。
- JH极高危亚组:RP的5年CSM为3.5%,EBRT为6.0%,多变量HR 0.58(95%CI 0.44-0.77,p<0.001) favoring RP。
- JH高危亚组:RP与EBRT的CSM无显著差异(HR 0.7,95%CI 0.39-1.25,p=0.2)。
临床怎么用
- 对于NCCN高危和JH极高危前列腺癌患者,RP可能提供优于EBRT的癌症特异性生存获益。
- 在JH高危亚组中,RP与EBRT的CSM无显著差异,治疗选择需个体化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our goal was to compare cancer-specific mortality (CSM) rates between radical prostatectomy (RP) vs external beam radiotherapy (EBRT) in National Comprehensive Cancer Network© (NCCN©) high risk (HR) patients, as well as in Johns Hopkins University (JH) HR and very high risk (VHR) subgroups. MATERIALS AND METHODS: Within the Surveillance, Epidemiology, and End Results database (2010-2016), we identified 24,407 NCCN HR patients, of whom 10,300 (42%) vs 14,107 (58%) patients qualified for JH HR vs VHR, respectively. Overall, 9,823 (40%) underwent RP vs 14,584 (60%) EBRT. Cumulative incidence plots and competing-risks regression addressed CSM after 1:1 propensity score matching (according to age, prostate specific antigen, clinical T and N stages, and biopsy Gleason score) between RP and EBRT patients. All analyses addressed the combined NCCN HR cohort, as well as in JH HR and JH VHR subgroups. RESULTS: In the combined NCCN HR cohort 5-year CSM rates were 2.3% for RP vs 4.1% for EBRT and yielded a multivariate hazard ratio of 0.68 (95% CI 0.54-0.86, p <0.001) favoring RP. In VHR patients 5-year CSM rates were 3.5% for RP vs 6.0% for EBRT, yielding a multivariate hazard ratio of 0.58 (95% CI 0.44-0.77, p <0.001) favoring RP. Conversely, in HR patients no significant difference was recorded between RP vs EBRT (HR 0.7, 95% CI 0.39-1.25, p=0.2). CONCLUSIONS: Our data suggest that RP holds a CSM advantage over EBRT in the combined NCCN HR cohort, and in its subgroup of JH VHR patients.
引用
- Chierigo F, Wenzel M, Würnschimmel C, et al. Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. J Urol. 2021. PMID: 34555930. doi:10.1097/JU.0000000000002250
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。